What primary outcome measures, including the Hernia‑Related Quality‑of‑Life questionnaire (HerQLes) and the Ventral Hernia Recurrence Inventory (VHRI), should be used in ventral hernia repair studies?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Primary Outcome Measures for Ventral Hernia Repair Studies

Ventral hernia repair studies should utilize both the Hernia-Related Quality-of-Life Survey (HerQLes) as the primary patient-reported outcome measure and the Hernia Recurrence Inventory (HRI, formerly VHRI) for long-term recurrence assessment, as these validated tools capture the most clinically meaningful endpoints of quality of life improvement and objective hernia recurrence.

Core Outcome Measures

HerQLes as the Primary Quality of Life Tool

  • The 12-question HerQLes survey is a validated, reliable instrument (internal consistency reliability 0.86) specifically designed to assess abdominal wall function and quality of life in ventral hernia patients 1
  • HerQLes demonstrates significant improvement following ventral hernia repair, with patients showing statistically significant QoL gains at 6 months and 1 year postoperatively 1, 2
  • The minimal clinically important difference (MCID) for HerQLes has been established at 15.6 points, providing a clear threshold for determining clinically meaningful improvement 3

Clinical Significance of HerQLes Scores

  • A 10-point improvement in HerQLes score correlates with a 3% decrease in surgical site infections and a 4% decrease in surgical site occurrences, demonstrating that subjective quality of life measures align with objective clinical outcomes 4
  • Patients with larger hernias (>6 cm) show greater improvement across 8 of 12 HerQLes components compared to smaller hernias, making it particularly valuable for assessing outcomes in complex repairs 2
  • Patients with increasing hernia width and higher ASA class have higher odds of exceeding the MCID threshold at 1 year, helping identify which patients will benefit most from repair 3

Hernia Recurrence Assessment

HRI (Formerly VHRI) for Long-Term Follow-Up

  • The Hernia Recurrence Inventory (HRI) is a validated patient-reported outcome tool that can accurately assess hernia recurrence through telephone administration, addressing the critical problem of patients lost to long-term follow-up 5
  • Self-reported bulge and patient perception of recurrence demonstrate high sensitivity (84-94%) and specificity (93-94%) for diagnosing hernia recurrence 5
  • Implementation of HRI in registries and research studies significantly improves long-term follow-up rates, which is essential given that recurrence is a key objective outcome measure 5

Standardized Time Points for Assessment

Recommended Assessment Schedule

According to consensus recommendations on surgical quality assessment, outcome measures should be collected at five standardized time points 6:

  • T0 (Pre-disease state): Baseline quality of life before hernia development
  • T1 (Pre-intervention): Disease state and symptoms a few days before surgery
  • T2 (Early postoperative): Immediate postoperative complications and early recovery
  • T3 (Mid-term): Disease and procedure-dependent (typically 6-12 months for hernia repair)
  • T4 (Long-term): Five years after intervention for assessment of recurrence and sustained QoL improvement 6

Additional Objective Outcomes

Complication Assessment

  • At minimum, use standardized complication grading systems (such as Clavien-Dindo classification) to ensure consistent reporting of postoperative morbidity 6
  • Track specific wound events including surgical site infections (superficial, deep, organ space), surgical site occurrences (seromas, hematomas), and those requiring procedural intervention (SSOPI) 4

Recurrence as Primary Endpoint

  • Hernia recurrence remains the most critical objective outcome measure, with significant variability based on mesh type and placement 7, 8
  • Recurrence assessment should extend to at least 12 months, though longer follow-up (5 years) is preferred to capture late recurrences 7, 6

Critical Considerations

Avoiding Common Pitfalls

  • Do not rely solely on in-person clinical examination for long-term recurrence assessment, as this leads to substantial loss of follow-up data; instead, implement HRI for remote assessment 5
  • Recognize that short-term mortality rates are no longer sufficient outcome measures given dramatically decreased perioperative mortality; focus must shift to morbidity and quality of life 6
  • Ensure both patient-centered outcomes (HerQLes, HRI) and objective clinical outcomes (complications, recurrence) are captured, as these measures correlate with each other and provide complementary information 4

Patient-Centered Approach

  • Patient education and empowerment are critical for meaningful outcome assessment 6
  • Incorporate at least one global life satisfaction measurement (such as EQ-5D) alongside hernia-specific tools to quantify overall change in quality of life over time 6
  • Recent evidence emphasizes that existing HRQoL tools, while useful, have developmental limitations and may benefit from further patient-informed refinement 9

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.